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Background: Pathogenesis of chronic obstructive lung disease (COPD) includes primary inflam-
matory events, multiple vascular reactions, remodeling of bronchial and vascular walls.
Objective: The aim of present single-center study was to assess relations between angiotensin-
converting enzyme (ACE ) gene and prevalence of clinical symptoms characteristic to COPD.
Methods: The study involved sixty-three male patients with COPD (44e86 years old, a mean of
60.4 years). COPD diagnostics was performed according to common criteria, including evalua-
tion of systolic pressure in pulmonary artery (SPPA) and endothelial disfunction (ED). Genotyp-
ing of ACE I/D was performed by means of gene-specific PCR.
Results: 1. Allele distribution of studied gene alleles among COPD patients did not differ from con-
trol age-matched group. 2. Detectable endothelial dysfunction in COPD patients was shown to
correlate with high-producer D allele of ACE gene, at an odds ratio of 6.632 (CIZ 1.67e26.31;
chi2Z 8.39, pZ 0.004). Moreover, detectable ED correlatedwith numbers of COPD exacerbations
per year.
Conclusions: These findings suggest possible association of the functionalACED allelewith altered
vascular responses that may modulate development of distinct COPD symptoms. The results are
obtained in a limited clinical cohort, and deserve repeated trials in other groups of COPD patients.
ª 2013 Elsevier Ltd. All rights reserved.7 812 4997194.
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1218 N.A. Kuzubova et al.IntroductionChronic obstructive disease (COPD) represents an impor-
tant, but yet unresolved issue in modern pneumology. Over
last years, a number of functional gene variants were
shown to predispose for COPD, or resistance to this disor-
der, in spite of harmful environmental factors, as listed
elsewhere.1 Current genome-wide studies show that there
is a universal set of variable genes, apparently associated
with COPD.2
ACE-1 (angiotensin-converting enzyme) is a widely
known regulatory protein. Clinical effects of ACE-1
depend on its ability to activate angiotensin-1, procolla-
genase enzymes, and to inactivate bradikinin by means of
a site-specific cleavage. Both vascular and collagenolitic
effects may be sufficient for COPD development. The ACE
gene controls production of active angiotensin II, thus
playing a significant role in genesis of vascular and renal
diseases (Sayed-Tabatabaei et al., 2006).3 ACE I/D poly-
morphism has been also studied in COPD patients. Unless
no correlation was found between COPD incidence and
ACE variants, the I/D polymorphism was shown to be
involved into muscular work efficiency in COPD patients.4
Another study5 has shown that presence of ACE I-allele
may predispose for a stable course of COPD (<3 exacer-
bations per year). A well-studied 287-bp insertion/dele-
tion (ACE I/D) polymorphism in intron 12 is a known
predictive marker for hypertension and cardiovascular
diseases, with D allele being associated with higher ACE-1
production.
Hence, the aim of present work was to test associations
between the bi-allelic polymorphism of ACE-1, and main
clinical symptoms of COPD in a sample of Russian popu-
lation. This limited single-center study has revealed sig-
nificant correlations between distinct clinical parameters
of the patients and appropriate “high-producer” gene
variant.Table 1 Clinical and demographic characteristics of COPD pati
Clinical features
Number of patients
Male gender
Caucasian origin (%)
Broncholytics administered, number of cases (%)
Mean age (M  m)
Smoking history, pack-years
Disease duration, years
Co-morbidities (arterial hypertension and/or
cardiovascular disease), number of patients
Number of exacerbations per year, M  m
Physical exercise tolerance (6-min walking test), m, M  m
Mean FEV1 predicted values, %, M  m
Residual pulmonary volume, % predicted values, M  m
Respiratory insufficiency, grade, M  m
Systolic pulmonary artery pressure, mm Hg, M  m
Note. Mean values (M  m) are shown in appropriate graphs.Patients and methods
Patients and their evaluation
Our study included sixty-three male patients with docu-
mented COPD history observed from 2004 to 2009 at the
Institute of Pulmonology at the St. Petersburg I.Pavlov
State Medical University (for clinical features see Table 1).
All the subjects were current or ex-smokers with a smoking
history of at least 20 pack-years, 44e86 years old (a mean
of 60.4  1.0 years). A control population group for geno-
typing consisted of 95 male persons without history of
COPD. They were recruited among laboratory and clinical
staff, bone marrow donors, and outpatients of St. Peters-
burg I. Pavlov Medical University adjusted for gender, age,
and comorbidity, at a mean age of 57.3  1.7 years. Of
them, 44 subjects (57%) were ex- or current smokers.
The diagnosis of COPD was based on subjective health
status, results of pulmonary function tests (FEV1/FVC
spirometry), conventional X-ray examination and CT scan-
ning. Clinical staging of the disease was performed ac-
cording to generally accepted GOLD criteria.6
Our study included COPD patients with stages II
(nZ 20), and III (nZ 43) of the disease (Table 1). A degree
of respiratory insufficiency was assessed from grade
0 (absence of dyspnea after a vigorous physical effort); to
grade II (dyspnea at usual everyday activities); grade III
(dyspnea in resting state). All patients received uniform
treatment, in accordance with recommendations of GOLD-
2009. I.e., an anticholinergic tiotropium bromide (18 mg/
day) was administered permanently, as a bronchodilator.
Beta-adrenoreceptor agonist salbutamol (100 mg) was used
on demand, as a dosed aerosol inhaler. In addition, the
patients with stage III COPD received inhalant glucocorti-
costeroids (beclomethasone dipropionate at a daily dose of
800 mg), throughout the 6-mo study. During COPD exacer-
bations, oral fluoroquinolones were administered.ents under study with vs without endothelial dysfunction.
Total group
of patients
Endothelial
dysfunction
absent
Endothelial
dysfunction,
present
P values
63 33 (52%) 30 (48%) e
63 (100%) 33 30 e
63 (100%) 33 30 e
63 (100%) 33 (100%) 30 (100%) e
60.4 þ 1.0 60.3  1.4 60.4  1.3 0.75
32.8  1.5 32.6  1.9 33.1  2.4 0.70
8.0  0.6 7.6  0.7 8.4  0.9 0.49
47/63 (75%) 24/33 (73%) 23/33 (77%) 0.55
2.4  0.2 2.1  0.3 2.7  0.2 0.006
357  11 369  14 346  16 0.09
45.1  2.4 42.5  3.5 47.4  3.3 0.30
179  7 178  8 181  11 0.94
1.6  0.1 1.5  0.1 1.8  0.1 0.08
37.8  1.0 37.4  1.3 38.2  1.5 0.95
ACE I/D alleles and endothelial dysfunction in COPD 1219Along with physical examination, the patients underwent
various functional studies, including assessment of systolic
pressure in pulmonary artery (SPPA). Choice of appropriate
method is of importance here. Direct right heart catheteri-
zation remains a golden standard for SPPA pressure mea-
surements.7 However, ultrasound technique is now regarded
as a plausible alternative.8 To compare results obtained by
these techniques, we have applied the both methods to
measure SPPA in thirty-seven COPD patients (for results, see
Table 1, Supplementary file). High degree of correlation was
revealed between SPPA values obtained by the both tech-
niques (r Z 0.95, p < 0.0001), thus allowing us to consider
Doppler echocardiography as a proper approach to deter-
mine systolic pressure in pulmonary artery. These data are in
accordance with previous studies.9 Thus, we used this
technique in all consequent patients from our study group.
An individual SPPA value represented a sum of amaximumTR
gradient and right atrial pressure, according to Rudski et al.10
Evaluation of endothelial dysfunction in brachial artery
was carried out, using a non-invasive Celermajer’s test for
reactive hyperemia.11 The baseline diameter of left
brachial artery was assessed by ultrasound technique, with
a linear sensor, followed by standard tonometric AP mea-
surement, with excessive compression of brachial area over
3 min, followed by repeated measurement of the vascular
diameter. Endothelial dysfunction was registered if post-
occlusion arterial dilatation response was <10% of the
baseline values.
The study was initiated and performed under written
informed consent and understanding of each participating
subject, in compliance with the Code of Ethics of the World
Medical Association, according to the Declaration of Hel-
sinki. The entire study design and all diagnostic procedures
were approved and observed by local institutional Ethics
Committee at the St. Petersburg State Medical I. Pavlov
University.Genotyping procedures
To study genetic associations with different COPD syn-
dromes, we have performed genotyping of biallelic intronicTable 2 ACE I/D genotype distribution and allele frequencies in
and in general population group.
Groups under study Number of cases ACE genotypes
I/I I/D
Control group 95 n: 24 49
f: 0.25 0.52
Total COPD group 63 n: 17 29
f: 0.27 0.46
ED absent 33 n: 14 11
f: 0.43 0.33
ED present 30 n: 3 18
f: 0.10 0.60
Note. Clinical data on endothelial dysfunction were available for 63 ca
are shown for the clinical subgroups studied. P values show levels of
a Total group of patients versus control group.
b Patients with versus without endothelial dysfunction.polymorphism in the ACE-1 gene (intron 12, I/D alleles).
Genotyping was successful in all the COPD patients and
controls. A control population group for genotyping con-
sisted of 95 male persons from St. Petersburg without COPD
adjusted for gender, age, and comorbidity, at a mean age
of 57.3  1.7 years. Of them, 44 subjects (57%) were ex- or
current smokers.
Genomic DNA was extracted from blood leukocytes of
patients and blood donors after cell lysis, and sorbent pu-
rification (Interlabservice, Moscow). To detect the inser-
tion/deletion alleles of ACE-1 genes, we used primers and
PCR conditions described elsewere.12 PCR products were
evaluated after electrophoresis in 2 per cent agarose gel
stained with Ethidium Bromide. The gel images were saved
and retrieved by means of a digital camera, Canon Power-
Shot A70.
Statistical evaluation
Calculations and analysis of genotype distributions were
performed by means of STATISTICA 6.0 software. Signifi-
cance of the differences obtained was assessed by
nonparametric criteria (c2 test, Spearman criterion). The
allele frequencies were calculated for separate clinical
subgroups and population controls. The 95% confidence in-
tervals (CI) of allele frequencies were calculated based on a
binomial distribution. Tests for deviations from Har-
dyeWeinberg equilibrium (HWE) were performed for all
subgroups, by Pearson’s goodness-of-fit c2 criterion, using
the DeFinetti approach (http://ihg.gsf.de/cgi-bin/hw/
hwa1.pl). A p-value of 0.05 was considered statistically
significant.Results
General characteristics of the patients
Frequencies of ACE I/D genotypes and alleles in COPD pa-
tients and matched control group are shown in Table 2. We
did not reveal any deviations from HardyeWeinberg rule forCOPD patients with vs without endothelial dysfunction (ED)
P values Numbers of
alleles
P values
D/D I D
22 >0.1a 97 93 >0.1a
0.23 0.51 0.49
17 63 63
0.27 0.50 0.50
8 0.004b 39 27 0.013b
0.24 0.59 0.41
9 24 36
0.30 0.40 0.60
ses. Numbers of genotypes or alleles (n), and their frequencies (f)
significance for different subgroups.
1220 N.A. Kuzubova et al.ACE I/D variants, both among COPD patients and control
group, as shown by HWE testing. No significant differences
in ACE I/D genotypes and alleles were found between COPD
patients and control age-matched population group.
Therefore, we have tested possible associations between
distinct functional gene variants and certain typical clinical
features of the COPD patients. Numbers of patients in
clinical subgroups were limited, due to single-center type
of the study. However, it allowed to calculate some asso-
ciations between the ACE alleles and frequency of distinct
COPD symptoms.
Using Spearman correlation tests, we did not reveal any
correlations between frequencies of ACE ID polymorphism
and most clinical symptoms of COPD listed in Table 1,
including smoking history, respiratory parameters, pulmo-
nary hypertension, physical tolerance (data not shown).
Endothelial dysfunction
In general, endothelial dysfunction (ED) was determined as
a deficient post-ishemic vascular dilatation. As shown in
Table 2, higher risk for ED in COPD was associated with ACE
D allele, at OR Z 6.632, CI Z 1.67e26.31; chi2 Z 8.39,
p Z 0.004. Frequency of a “high-producer” ACE D allele
was significantly higher among COPD patients with endo-
thelial dysfunction than among ED-free patients
(p Z 0.013). In general, endothelial dysfunction (ED) in
COPD patients did correlate with harboring the ACE D allele
(r Z 0.365; p Z 0.002), according to Spearman criterion.
With respect to clinical features, presence of ED correlated
with number of exacerbations per year (r Z 0.29;
p Z 0.009).
Discussion
A pulmonary hypertension syndrome, or “lung arterioscle-
rosis with enlargement of right heart ventricle” was
described by Romberg in 1891. Histomorphological studies
in PH demonstrate some typical alterations of small pul-
monary arteries, i.e.,: 1) development of smooth muscle
layers in previously muscle-free arteries within a respira-
tory sinus; 2) increased muscle layer in more proximal ar-
teries; 3) elastin and collagen type 1 deposits leading to
increased hardness of vascular walls; 4) disorganization of
endothelial layer, with formation of plexiform structures.13
As based on a vascular origin of pulmonary hypertension,
one may consider abnormal responses to vasoconstrictor
factors (angiotensin, serotonin etc.), in vascular walls.
Probable factors of respiratory insufficiency in COPD are
connected both with fibrotic events in the lung alveoli, and
with altered blood circulation, due to narrowing of vascular
lumen. A primary factor of lung damage in COPD still
remains open, in spite of many well-known exogenous
reasons (smoking, toxic aerosol inhalation, ozone effects
etc.). On other hand, a possible participation of vascular
component in bronchoalveolar deterioration deserves spe-
cial attention.
The data about higher frequency of ACE-1 D allele
harboring in patients with endothelial dysfunction seems to
be the most relevant finding. Higher prevalence of endo-
thelial dysfunction in cases of ACE-1/D genotype is shown invarious physiological and disease states.3,14 It may be pre-
sumed that, along with altered endothelial responses, the D
allele of ACE-1 gene increases capillary permeability, due
to increased production of ACE, enhanced angiotensin II
activation, as well as bradikinin degradation.15
Hence, a high-producer D allele of ACE-1 gene seems to
be associated with endothelial dysfunction in COPD pa-
tients, thus confirming a pathogenetic significance of this
well-studied gene polymorphism which is known to predis-
pose for various types of other common vascular disorders.
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